• Subjects were required to have heterozygous familial hypercholesterolemia, established CAD, or coronary heart disease risk equivalent
  • Average baseline LDL was 122 mg/dl
  • All patients also took maximally-tolerated statins
  • Reference [2]
Alirocumab (Ali) vs placebo for 24 weeks in patients at high-risk for cardiovascular disease
Lipid Ali 150 mg every 2 weeks
(N=1530)
Placebo
(N=780)
LDL
(% change from baseline)
-61% 0.8%
Total
(% change from baseline)
-38% -0.3%
HDL
(% change from baseline)
4.0% -0.6%
Triglycerides
(% change from baseline)
-15.6% 1.8%

  • Subjects had hyperlipidemia and were taking atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg
  • Average baseline LDL was 77 - 127 mg/dl across the five background therapy arms
  • Non-HDL-C = total cholesterol - HDL
  • Reference [3]
Evolocumab (Evo) for 12 weeks in patients taking statins
Lipid Evo 140 mg every 2 weeks
(N=555)
Evo 420 mg once monthly
(N=562)
LDL
(difference from placebo)
-71% -63%
Total
(difference from placebo)
-40% -36%
Non-HDL-C
(difference from placebo)
-59% -54%
Apo B
(difference from placebo)
-55% -50%